Shares of NRx Pharmaceuticals, Inc. (NRXP) are down over 32% at $2.40 in premarket trading today, following the release of results from a phase IIb/III trial of NRX-101 in treatment of suicidal bipolar depression.
In the study, NRX-101 demonstrated a 33% reduction in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia relative to Lurasidone, according to the company.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com